{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:39:19Z","timestamp":1762868359957,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejca.2020.11.037","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T09:05:08Z","timestamp":1608887108000},"page":"200-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era"],"prefix":"10.1016","volume":"144","author":[{"given":"V\u00edctor","family":"Rodriguez-Freixinos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alia","family":"Thawer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dermot","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staffan","family":"Welin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Grozinsky-Glasberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teodora","family":"Kolarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Bouvier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"www.worldometers.info\/coronavirus.","key":"10.1016\/j.ejca.2020.11.037_bib1"},{"key":"10.1016\/j.ejca.2020.11.037_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"unstructured":"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-guidance-management-patients.html.","key":"10.1016\/j.ejca.2020.11.037_bib3"},{"issue":"3","key":"10.1016\/j.ejca.2020.11.037_bib4","first-page":"335","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Lancet","volume":"21","author":"Liang","year":"2020","journal-title":"Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2020.11.037_bib5","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.18632\/aging.103000","article-title":"Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis","volume":"12","author":"Wang","year":"2020","journal-title":"Aging"},{"issue":"6","key":"10.1016\/j.ejca.2020.11.037_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Canc Discov"},{"doi-asserted-by":"crossref","unstructured":"The Medical Journal of Australia. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Available at: https:\/\/www.mja.com.au\/journal\/2020\/212\/10\/managing-haematologyand-oncology-patients-during-covid-19-pandemic-interim. Accessed March 26, 2020.","key":"10.1016\/j.ejca.2020.11.037_bib7","DOI":"10.5694\/mja2.50607"},{"unstructured":"Ontario Health Cancer Care Ontario. Pandemic planning clinical guideline for patients with cancer. [cited 2020 Apr 9]; available from: https:\/\/www.accc-cancer.org\/docs\/documents\/cancerprogram- fundamentals\/oh-cco-pandemic-planning-clinicalguideline_ final_2020-03-10.pdf?sfvrsn=d2f04347_2].","key":"10.1016\/j.ejca.2020.11.037_bib8"},{"unstructured":"ESMO COVID-19 and cancer. [cited 2020 Apr 9]; available from: https:\/\/www.esmo.org\/covid-19-and-cancer].","key":"10.1016\/j.ejca.2020.11.037_bib9"},{"unstructured":"ASCO coronavirus resources. [cited 2020 Apr 9]; available from: https:\/\/www.asco.org\/asco-coronavirus-information].","key":"10.1016\/j.ejca.2020.11.037_bib10"},{"unstructured":"NCCN. Coronavirus disease 2019 (COVID-19) resources for the cancer care community. [cited 2020 Apr 9]; available from: https:\/\/www.nccn.org\/covid-19\/].","key":"10.1016\/j.ejca.2020.11.037_bib11"},{"unstructured":"American College of Surgeons. ACS: COVID-19 and surgery. [cited 2020 Apr 10]; available from: https:\/\/www.facs.org\/covid19\/clinical-guidance. https:\/\/www.essoweb.org\/news\/esso-statementcovid-19\/.","key":"10.1016\/j.ejca.2020.11.037_bib12"},{"unstructured":"American Society for Radiation Oncology (ASTRO). COVID-19 recommendations to radiation oncology practices. [cited 2020 Apr 10]; available from: https:\/\/www.astro.org\/Daily-Practice\/%20COVID-19-Recommendations-and-Information.","key":"10.1016\/j.ejca.2020.11.037_bib13"},{"issue":"20","key":"10.1016\/j.ejca.2020.11.037_bib14","first-page":"31173","article-title":"UK Coronavirus Cancer Monitoring Project Team, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"S0140-6736","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ejca.2020.11.037_bib15","first-page":"31187","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"S0140-6736","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2020.11.037_bib16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.11.037_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MPA.0000000000001561","article-title":"North American neuroendocrine tumor society guide for neuroendocrine tumor patient health care providers during COVID-19","author":"Bergsland","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.ejca.2020.11.037_bib18","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0279","article-title":"A neuroendocrine tumor specialty center in new Orleans' (NOLANETS) response to patient care during the COVID-19 pandemic","author":"Ramirez","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ejca.2020.11.037_bib19","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1200\/JOP.2010.000098","article-title":"Multidisciplinary reference centers: the care of neuroendocrine tumors","volume":"6","author":"Singh","year":"2010","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ejca.2020.11.037_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/OP.20.00199","article-title":"Telehealth in oncology during the COVID-19 outbreak: bringing the house call back virtually","author":"Liu","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ejca.2020.11.037_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/OP.20.00281","article-title":"Virtual cancer care during and beyond the COVID-19 pandemic: we need to get it right","author":"Meti","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"20","key":"10.1016\/j.ejca.2020.11.037_bib22","first-page":"36394","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"S0923-7534","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2020.11.037_bib23","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jamaoncol.2018.2428","article-title":"Commonwealth neuroendocrine tumour collaboration (CommNETS) follow-up working group. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors","volume":"4","author":"Singh","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.11.037_bib24","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2020.11.037_bib25","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.119.6.1647","article-title":"Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature","volume":"119","author":"Fink","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ejca.2020.11.037_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.037_bib27","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2020.11.037_bib28","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40273-018-0656-z","article-title":"Costs of cancer care for elderly patients with neuroendocrine tumors","volume":"36","author":"Shen","year":"2018","journal-title":"Pharmacoeconomics"},{"unstructured":"https:\/\/www.sirweb.org\/practiceresources\/covid-19-resources.","key":"10.1016\/j.ejca.2020.11.037_bib29"},{"key":"10.1016\/j.ejca.2020.11.037_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.037_bib31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.037_bib32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"28","author":"Pavel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.037_bib33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreaticneuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.037_bib34","first-page":"m143","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ejca.2020.11.037_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jvs.2020.05.015","article-title":"The need to manage the risk of thromboembolism in COVID-19 patients","volume":"72","author":"Khan","year":"2020","journal-title":"J Vasc Surg"},{"unstructured":"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/disposition-hospitalized-patients.html.","key":"10.1016\/j.ejca.2020.11.037_bib36"},{"unstructured":"https:\/\/www.nice.org.uk\/guidance\/ng161.","key":"10.1016\/j.ejca.2020.11.037_bib37"},{"unstructured":"https:\/\/www.facs.org\/\/media\/files\/covid19\/acs_triage_and_management_elective_cancer_surgery_during_acute_and_recovery_phases.ashx.","key":"10.1016\/j.ejca.2020.11.037_bib38"},{"key":"10.1016\/j.ejca.2020.11.037_bib39","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.037_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study","volume":"23","author":"Caplin","year":"2016","journal-title":"Endocr Relat Canc"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.037_bib41","first-page":"7","article-title":"ENETS 2016 munich advisory board participants; ENETS 2016 munich advisory board participants","volume":"108","author":"Baudin","year":"2019","journal-title":"Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms Neuroendocrinology"},{"key":"10.1016\/j.ejca.2020.11.037_bib42","first-page":"1","article-title":"Radionuclide therapy in the time of COVID-19","author":"Brabander","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejca.2020.11.037_bib43","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.037_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/02841869309083913","article-title":"An update of the medical treatment of malignant endocrine pancreatic tumors","volume":"32","author":"Eriksson","year":"1993","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2020.11.037_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.ejca.2020.11.037_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Canc"},{"issue":"6","key":"10.1016\/j.ejca.2020.11.037_bib47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1159\/000444087","volume":"103","author":"Spada","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2020.11.037_bib48","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.2016.70.4072","article-title":"Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518","volume":"35","author":"Yao","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.037_bib49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ejca.2020.11.037_bib50","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.clinthera.2018.10.008","article-title":"Relationship between symptoms and health related quality of life benefits in patients with carcinoid syndrome: post-hoc analyses from TELESTAR","volume":"40","author":"Cella","year":"2018","journal-title":"Clin Therapeut"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2020.11.037_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","article-title":"Interferon in the management of neuroendocrine GEP-tumors: a review","volume":"62","author":"Oberg","year":"2000","journal-title":"Digestion"},{"issue":"6","key":"10.1016\/j.ejca.2020.11.037_bib52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.dld.2020.03.031","article-title":"COVID-19 epidemic: proposed alternatives in the management of digestive cancers: a French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)","volume":"52","author":"Di Fiore","year":"2020","journal-title":"Dig Liver Dis"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:35Z","timestamp":1760733095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":52,"alternative-id":["S0959804920313745"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.037","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}